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1INTEREST OF AMICUS CURIAE1
InVitae Corporation (“InVitae”) is a San Francisco, 
California-based company providing genetic testing and 
genome management services based on human DNA 
sequencing. InVitae’s goal is to aggregate all the world’s 
genetic tests into a single assay with higher quality, faster 
turn-around time, and at a lower cost than most single gene 
tests performed today. InVitae is one of many companies in 
a rapidly evolving industry utilizing advances in massively 
parallel DNA sequencing to analyze large numbers of 
genes, as well as to sequence whole genomes or large 
regions of the genome for diagnostic purposes. See, e.g., 
Tracy Tucker et al., Massively Parallel Sequencing: The 
Next Big Thing in Genetic Medicine, 85 Am. J. Hum. 
Genet. 142, 142 and 148-152 (2009), available at http://
www.ncbi.nlm.nih.gov/pmc/articles/PMC2725244/. The 
future and promise of personalized medicine rests on the 
ability of medical practitioners to access comprehensive 
information about patients’ genetic information, including 
whether a patient possesses clinically relevant variations 
in any of a broad panel of human genes. Id. 
Since the 1990s when the sequencing of the  rst full 
human genome began, the technologies and chemistry 
available for genomic sequencing have evolved rapidly. 
While the  rst genome was sequenced at a cost of $437 
1. No person other than the amicus curiae or their counsel 
has made any monetary contribution to the preparation or 
submission of this brief. Further, no counsel for any party authored 
this brief in whole or in part. Petitioners have lodged a blanket 
consent to the  ling of amicus briefs, and a letter of consent to 
the  ling of this brief by Respondents has been lodged with the 
Clerk of the Court.
2million over 13 years,2 today’s widely available “Next 
Generation” methods can, with a single laboratory assay, 
sequence the genome of an individual patient in a few days 
at costs of around $5,000 - $10,000, and sequencing subsets 
of a patient’s genes or the complete set of roughly 20,000 
genes (called “the exome”) cost well below $1,000 today.3 
Current estimates suggest that these prices will continue 
to decline rapidly thereby greatly expanding the uses and 
market for large scale DNA sequencing. See, e.g., Matthew 
Harper, Biotech Firms Battle Over Same Day Genomes, 
Forbes Magazine, January 10, 2012, available at http://
www.forbes.com/sites/matthewherper/2012/01/10/biotech-
 rms-battle-over-same-day-genomes; Christianne Bird, 
Next-Gen Sequencing Services: An Expanding Role in 
Clinical Applications Opens New Markets, Genet. Eng’g 
& Biotech. News, May 1, 2012, http://www.genengnews.
com/gen-articles/next-gen-sequencing-services/4088/; 
Ivan Karabaliev, The $1,000 Genome is Almost Here—
Are We Ready?, Scienti c American, Oct. 15, 2012, http://
blogs.scientificamerican.com/guest-blog/2012/10/15/
the-1000-genome-is-here-are-we-ready. Comprehensive 
genetic information has become both affordable and 
2. E.g., U.S. Dept. of Energy Genome Programs, Human 
Genome Project Information (2004), http://www.ornl.gov/sci/
techresources/Human_Genome/project/budget.shtml.
3. Some observers have likened the exponentially rapid pace 
of change in the speed and cost reduction for genomic sequencing 
technology to Moore’s Law which states that “[t]he number of 
transistors on a [semiconductor] chip will double approximately 
every 24 months.” See, e.g., Moore’s Law and Intel Innovation, 
http://www.intel.com/content/www/us/en/silicon-innovations/
moores-law-consumer-technology.html; National Human Genome 
Research Institute, Cost per Genome (2012), http://www.genome.
gov/images/content/cost_per_genome.jpg.
3easily available to clinicians and researchers to help them 
improve human health.
Current commercially available genomic sequencing 
technologies achieve such great improvements in speed 
and ef ciency through massively parallel processes. See, 
e.g., Tucker, supra at 142. A patient’s genetic information 
is determined by collecting a sample of the patient’s DNA, 
breaking those DNA molecules into millions of fragments 
and simultaneously copying and sequencing all or some 
of those fragments side by side. Id. at 142-144. InVitae 
is concerned that patents claiming individual human 
genes or fragments of such individual human genes, if 
asserted, could impair a patient’s ability to have his or 
her own relevant genetic information sequenced for use in 
connection with the patient’s own medical care. A patent 
holder might claim that one of those millions of gene 
fragments being sequenced is putatively covered by a claim 
to a speci c gene fragment. Worse, in the circumstance in 
which there are multiple distinct patentees each claiming a 
different gene, any one patentee could threaten to prevent 
the sequencing of a patient’s exome or entire genome 
because such sequencing necessarily includes sequencing 
each human gene contained in the human genome. Worse 
yet, within any individual gene there could be hundreds 
or even thousands of individual mutations identi ed and 
separately patented as they are discovered so that no 
single patentee could permit the sequencing of such a 
gene. No patent should foreclose an individual’s right to 
self-knowledge of their own genetic information. 
InVitae is a strong believer in the importance of a vital 
U.S. patent system. Nonetheless, InVitae is concerned 
that some patentees holding patent claims on speci c 
4genes or on individual mutations within a gene could 
foreclose its ability to provide patients with access to 
their genetic information which is naturally present in 
the human genome as well as preventing the research and 
commercial life sciences communities from developing 
further understanding of the medical significance of 
aspects of that genetic information. A circumstance in 
which myriads of genes and variations in the human 
genome are privatized through separate patents could 
substantially impair the development of the genomic 
testing industry and erode U.S. competitiveness in a 
critical area of healthcare innovation. 
SUMMARY OF ARGUMENT
The human genome is constituted of human genes 
and other related sequences which are naturally 
occurring information. With respect to a human gene, 
such information includes the normal (or wild type) 
sequence as well as common and uncommon variants of 
the sequence and associations between such variations 
and medical conditions or predispositions. This Court 
has long held that laws of nature and pre-emption of 
their use are not patentable subject matter. E.g., Mayo 
Collaborative Services v. Prometheus Laboratories, 
Inc., 132 S. Ct. 1289, 1294-1295 (2012). Human genetic 
information, including sequences of human genes, gene 
fragments and correlations between variations in human 
genes and medically relevant patient information all 
constitute laws of nature akin to the correlation between 
drug metabolite concentrations measured in a patient and 
the determination of the suitable drug dosage for that 
patient which was found to be a law of nature under the 
Mayo test for patentable subject matter. Id. at 1296-1297.
5Patent claims which pre-empt the use of laws of nature 
in the form of human genetic information embrace patent 
ineligible subject matter. Even if a patent claim is directed 
to a gene as a composition of matter, that gene is de ned 
in terms of its genetic sequence and it embodies a law 
of nature in the form of the relevant genetic sequence. 
Consequently, to the extent that patent claims to nucleic 
acids de ned with respect to human gene sequences (or 
fragments thereof or variations therein) can pre-empt the 
use of a law of nature including uses such as determining 
a patient’s genetic sequence, the patent claim is directed 
to unpatentable subject matter. 
The opinions of the Court of Appeal illustrate a tension 
between (1) the majority’s view of a patent claim directed 
to an isolated nucleic acid as a patentable composition of 
matter distinct from the gene in its native chromosome 
and (2) the dissent’s view of such a claim as unpatentable in 
that it may pre-empt the use of a law of nature in the form 
of the claimed sequence information. Amicus suggests a 
rule of claim construction for human gene patents that 
would exclude as patent ineligible from the scope of a 
patent claim any subject matter to the extent it serves to 
pre-empt the use of a law of nature. Such a rule of claim 
construction could preserve claims to human genes, to the 
extent that they claim additional inventive subject matter 
beyond the patent ineligible law of nature—any portion 
of the sequence of the human gene—or otherwise cover 
compositions of matter in contexts where their use would 
not preempt a law of nature. 
6ARGUMENT
I. UNDER THE MAYO STANDARD, SEQUENCES 
OF HUMAN GENES AND GENE FRAGMENTS, 
AND VARIATIONS IN THEIR SEQUENCES, 
SHOULD BE CONSIDERED UNPATENTABLE 
LAWS OF NATURE.
The human genome is fundamentally information 
and DNA is simply nature’s most ef cient information 
storage and retrieval device.4 Nucleic acids, principally 
DNA in the form of long sequences comprised of four 
nucleotide bases (adenine, thymine, guanine, and cytosine, 
or A, T, G and C), embody this information.5 It consists 
of 23 pairs of chromosomes with each chromosome 
including a sequence of between approximately 50 million 
to 250 million base pairs long which together include 
approximately 20,000 human genes.6 Each embodiment of 
4. Recent reports of the encoding of the entire collection of 
Shakespeare’s sonnets in a single DNA molecule (weighing much 
less than a billionth of a gram) illustrates the extraordinary 
data storage capacity of nucleic acids. See, e.g., Ian Sample, 
Shakespeare and Martin Luther King demonstrate potential of 
DNA storage, The Guardian, Jan. 24, 2013, http://www.guardian.
co.uk/science/2013/jan/23/shakespeare-sonnets-encoded-dna.
5. The decisions below discuss the nature of the human 
genome, nucleic acids and the genetic code in some detail, and 
InVitae will not revisit the science here except in a summary 
fashion. 
6. While less than 2% of the full human genome is made up 
of genes, all of its 3 billion base pairs are inheritable information. 
See, e.g., Brendan Maher, ENCODE: The Human Encyclopedia, 
Nature, Sept. 5, 2012, at 46, 46, available at http://www.nature.
com/news/encode-the-human-encyclopaedia-1.11312. As its role 
becomes better understood, the clinical signi cance of the non-
7a human gene in a human cell includes a genetic sequence 
providing the information necessary for the expression of 
a corresponding protein. Not every occurrence of a speci c 
human gene, however, has an identical sequence and 
variations in those sequences can give rise to differences 
in the proteins expressed from those genes. 
Even though much of the sequence information in 
the human genome is consistent from person to person, 
there are millions of speci c variations which have been 
identi ed. In an ever-increasing number of cases, these 
individual variations or certain collections of variations 
are being identi ed as correlating to certain diseases 
or increased risks of contracting certain diseases.7 The 
sequences of human genes, variations and mutations 
in these genes observed in individual patients are all 
naturally occurring information. Even fragments of more 
than a few nucleotides in length can act as distinctive 
“bookmarks” within the human genome and thus serve 
as a tool to reference a particular gene, and consequently 
they too are “laws of nature” which are highly relevant to 
the act of sequencing their corresponding gene. Similarly, 
the correlations between this genetic information and 
medically relevant information such as diagnosis of a 
disease, susceptibility to certain diseases, responsiveness 
to certain pharmaceuticals, and likelihood of adverse 
reactions to certain pharmaceuticals constitute naturally 
occurring information. Access to this genetic information 
gene sequences to patient care may come to rival that of human 
genes. Id. at 46-48.
7. BRAC1 and BRCA2, the subject matter of the patents at 
issue in the case below, are merely two examples of human genes 
for which certain variations have been identi ed as correlated 
with risk of certain diseases.
8is becoming increasingly important in routine patient 
medical care as its costs have plummeted.8
This Court has held that while the Patent Act de nes 
categories of patentable subject matter, 35 U.S.C. 
101, laws of nature and pre-emption of their uses are 
nonetheless excluded. Mayo, 132 S. Ct. at 1294-1295 
and 1302. Speci cally, the Court in Mayo found that 
an observed correlation between the concentrations of 
certain metabolites of an administered drug in a patient 
and the clinical suitability of the administered dosage 
of that drug for that patient constituted a law of nature 
for the purposes of determining that patent claims 
directed to such correlations did not constitute patentable 
subject matter. Id.at 1296-1297. By analogy to the Mayo 
decision, human genomic information including a patient’s 
sequence for a particular gene, the presence or absence 
of variations in the genetic sequence and associations 
between that sequence information and medically relevant 
consequences are all laws of nature. In comparison with 
the metabolite correlations at issue in Mayo, the sequences 
of human genes and information relating naturally 
occurring variations in human genes to diagnoses and 
other patient care are more fundamental and more of a 
law of nature than a correlation between metabolites and 
suitable dosage for a drug where the correlation is based 
upon administration of the particular drug.9 
8. While the  rst human genome was completed in 2003 at a 
cost of hundreds of millions of dollars, today, just ten years later 
the cost is approaching a thousand dollars. See, e.g., Tucker, supra 
at 142; Harper, supra; Karabaliev, supra.
9. Other correlations with genetic information—such as use 
of certain genetic markers to identify patients who are suitable for 
a particular pharmaceutical treatment or susceptible to certain 
9II. PAT EN T CL A I MS T O H U M A N GEN ES , 
GEN E FR AGMEN T S A N D VA RI ATIONS 
SHOULD BE CONSTRUED TO EXCLUDE AS 
UNPATENTABLE SUBJECT MATTER ALL 
GENETIC INFORMATION CONSTITUTING A 
LAW OF NATURE
Patent claims directed to human genes are frequently 
drafted such that the sole distinctive feature of the claim 
is the sequence of the gene or a fragment of the gene.10 
While such human gene claims are styled as claims to a 
composition of matter or molecule such as an “isolated gene” 
having a particular genetic sequence or an “isolated nucleic 
acid” having a particular genetic sequence, the de ning 
characteristic of such human gene claims is presented with 
reference to the genetic sequence information embodied by 
such a molecule. In its holding below, the Federal Circuit 
majority emphasized the distinction between an isolated 
nucleic acid molecule having a sequence for a human gene 
(or a fragment of a human gene) and the same sequence as 
it appears naturally within a human chromosome. Ass’n 
for Molecular Pathology v. U.S. P.T.O., 689 F.3d 1303, 
1341-1344 (Fed. Cir. 2012). The majority’s reliance upon 
the isolation of a claimed gene or gene fragment fails 
to account for the fact that such a claim to an isolated 
adverse effects of certain pharmaceuticals—would constitute 
correlations which are laws of nature analogous to the correlation 
found to be a law of nature in the Mayo decision.
10. Such gene sequences are typically de ned in terms of a 
sequence of nucleotides or a sequence of amino acids for which 
the gene codes. By way of illustration, Claim 1 of U.S. Patent 
5,747,282 reads as follows: “1. An isolated DNA coding for a BRCA1 
polypeptide, said polypeptide having the amino acid sequence set 
forth in SEQ ID NO:2.” 2J.A. 821.
10
gene may nonetheless be exploited to pre-empt a law of 
nature—the human gene sequence it embodies.
The pre-emptive effect of a patent claim is measured 
by the properly construed scope of the claim in the 
context of the statutorily de ned categories of activities 
which constitute patent infringement. See, e.g., Markman 
v. Westview Instruments, Inc., 517 U.S. 370, 372-374 
(1996). The Patent Act provides that the activities of, 
inter alia, making or using a claimed composition of 
matter constitute patent infringement. 35 U.S.C. 271. 
Consequently, activities involving the making or using of 
an isolated nucleic acid having the sequence of a claimed 
human gene (or human gene fragment) in the course 
of determining a patient’s genetic sequence could be 
asserted to pre-empt the use of such a law of nature. For 
example, the determination of a patient’s genetic sequence 
typically entails the steps of extracting genetic material 
from a biological sample (blood, saliva, biopsy, etc.) from 
the patient, digesting the genetic material into numerous 
fragments, selecting some or all of the fragments for 
analysis, making copies of the selected fragments and 
then reading the sequences of the fragments. Using a 
claim covering an isolated human gene fragment to stop 
the making of copies of such fragments and the using of 
such fragments in the course of determining a patient’s 
genetic sequence information would pre-empt the use of 
a law of nature and therefore should be excluded from the 
patentee’s monopoly provided by a patent. By contrast, to 
the extent that a claim referencing a human gene includes 
other inventive subject matter and/or does not serve to 
pre-empt the exploitation of a law of nature such other 
subject matter should remain patent eligible subject to 
11
the other requirements governing patent eligibility under 
35 U.S.C. 101 and this Court’s precedents. 
CONCLUSION
For the foregoing reasons, the amicus curiae InVitae 
Corporation respectfully suggests that the Court consider 
(i) adopting a rule of construction of patent claims to 
exclude from the scope of the claims that subject matter 
which serves to pre-empt the use or exploitation of a law of 
nature and (ii) con rming that human genetic information, 
including sequences, variations and correlations between 
such variations and medical consequences thereof, all 
constitute patent ineligible laws of nature. 
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